Theragnostics is a privately held clinical stage radiopharmaceutical company that is developing a complete portfolio of products for the management and treatment of cancer patients, from initial diagnosis to treatment planning and monitoring, to therapy.
Ian is a serial entrepreneur who has raised more than $2B in sectors ranging from Information Technology to energy to pharmaceuticals. Prior to founding Theragnostics, Ian started two pharmaceutical companies, Medeva and Skyepharma, both of which went public under his leadership and ultimately reached multi-billion dollar valuations.
Chief Executive Officer
Greg has a career spanning 20-years in radiopharmaceutical research and development. He has gained extensive regulatory, product and clinical development experience doing research and development of vaccines at the U.S. National Institutes of Health. Greg returned to the UK to King’s College London (KCL), where his group developed imaging biomarkers for autoimmunity, heart disease and oncology. While at KCL he co-invented the Galli® technology at the centre of Theragnostics’ proprietary platform. He later became Director of R&D for Oxford Immunotec with responsibility for translating in vitro diagnostic products from bench to bedside.
Chief Executive Officer, Theragnostics Inc.
Pat joined Theragnostics from Blackthorn Associates, LLC, which focuses on technology and market evaluation, development and program management in the fields of nuclear medicine and radiation therapy. Pat has more than 20 years of experience in these fields and counselled international clients in marketing and sales, business development, project management and technology development.
As Director of North American Operations for Eckert & Ziegler Eurotope GmbH he established the North American business entity and launched the IGG100 Gallium-68 Generator and Modular-Lab PET tracer synthesis technology product lines. Earlier, he held senior positions at QSA Global, Alliant Medical, and DuPont Radiopharmaceuticals.
Pat served on the Society for Nuclear Medicine and Molecular Imaging, Radiopharmaceutical Sciences Council and is a past president of the Boston Chapter of the International Society for Pharmaceutical Engineering. He holds a BS in Chemical Engineering from Worcester Polytechnic Institute, an MBA from Boston University, and is a Registered Professional Engineer.
Chief Operations Officer
Gareth has over 10 years of experience in working in the field of medical imaging. Having gained his PhD in Chemistry at King’s College London with a focus on new probe development for Positron Emission Tomography (PET) he joined GE Healthcare as a Radiochemist in research and development. During his time with GE, Gareth worked on a wide range of projects and as well s developing a broad knowledge of PET and SPECT was involved with analysis of IP projects and competitive intelligence.
With a strong interest in technology licensing gained from his time at GE he went on to join Oxford University Innovation where he was involved in protecting IP from the University of Oxford and licensing IP to pharma and technology companies. Gareth also supported the raising of funds for translational research and equity finance to develop spin-out companies from Oxford.